AU694602B2 - Novel peptide - Google Patents

Novel peptide

Info

Publication number
AU694602B2
AU694602B2 AU44272/96A AU4427296A AU694602B2 AU 694602 B2 AU694602 B2 AU 694602B2 AU 44272/96 A AU44272/96 A AU 44272/96A AU 4427296 A AU4427296 A AU 4427296A AU 694602 B2 AU694602 B2 AU 694602B2
Authority
AU
Australia
Prior art keywords
peptide
leu
cells
amino acids
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44272/96A
Other languages
English (en)
Other versions
AU4427296A (en
Inventor
Nicholas Manolios
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northern Sydney and Central Coast Area Health Services
Original Assignee
Northern Sydney Area Health Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN0590A external-priority patent/AUPN059095A0/en
Priority claimed from AUPN0589A external-priority patent/AUPN058995A0/en
Application filed by Northern Sydney Area Health Service filed Critical Northern Sydney Area Health Service
Priority to AU44272/96A priority Critical patent/AU694602B2/en
Publication of AU4427296A publication Critical patent/AU4427296A/en
Application granted granted Critical
Publication of AU694602B2 publication Critical patent/AU694602B2/en
Assigned to NORTHERN SYDNEY AND CENTRAL COAST AREA HEALTH SERVICE reassignment NORTHERN SYDNEY AND CENTRAL COAST AREA HEALTH SERVICE Request to Amend Deed and Register Assignors: NORTHERN SYDNEY AREA HEALTH SERVICE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
AU44272/96A 1995-01-16 1996-01-16 Novel peptide Ceased AU694602B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44272/96A AU694602B2 (en) 1995-01-16 1996-01-16 Novel peptide

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPN0590A AUPN059095A0 (en) 1995-01-16 1995-01-16 Novel lipopeptide
AUPN0590 1995-01-16
AUPN0589A AUPN058995A0 (en) 1995-01-16 1995-01-16 Novel peptide
AUPN0589 1995-01-16
AU44272/96A AU694602B2 (en) 1995-01-16 1996-01-16 Novel peptide
PCT/AU1996/000018 WO1996022306A1 (en) 1995-01-16 1996-01-16 Novel peptide

Publications (2)

Publication Number Publication Date
AU4427296A AU4427296A (en) 1996-08-07
AU694602B2 true AU694602B2 (en) 1998-07-23

Family

ID=25644844

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44272/96A Ceased AU694602B2 (en) 1995-01-16 1996-01-16 Novel peptide

Country Status (8)

Country Link
US (1) US6057294A (enExample)
EP (1) EP0804469B1 (enExample)
JP (3) JP3665342B2 (enExample)
AU (1) AU694602B2 (enExample)
CA (1) CA2210812C (enExample)
DE (1) DE69617396T2 (enExample)
ES (1) ES2168456T3 (enExample)
WO (1) WO1996022306A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69617396T2 (de) * 1995-01-16 2002-09-05 Northern Sydney Area Health Service, St. Leonards T-Zellen beeinflussende Peptide
WO1997035881A2 (en) * 1996-03-27 1997-10-02 Ng Gordon Y K Receptor and transporter antagonists
CA2257973C (en) 1996-06-11 2010-02-02 Northern Sydney Area Health Services T cell antigen receptor peptides
US20050070478A1 (en) * 1996-06-11 2005-03-31 Northern Sydney Area Health Services T cell antigen receptor peptides
BR9808529B1 (pt) 1997-04-11 2010-10-05 oligopeptìdeo.
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
JP2003534287A (ja) * 2000-05-19 2003-11-18 ユニバーシティ・オブ・メリーランド， ボルティモア 糖尿病発症を予防または遅延させるためのゾヌリンのペプチドアンタゴニストの使用方法
US7094413B2 (en) 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
CA2565886A1 (en) * 2004-05-27 2005-12-08 Gropep Limited Treatment of inflammatory airway disease
WO2007034490A2 (en) * 2005-09-22 2007-03-29 Yeda Research And Development Co. Ltd., At The Weizmann Institute Of Science Diastereomeric peptides for modulating t cell immunity
EP1870420A1 (en) * 2006-06-23 2007-12-26 Max-Delbrück-Centrum Für Molekulare Medizin Peptides regulating the surface expression of the T cell receptor
US20120077732A1 (en) * 2008-11-24 2012-03-29 Sydney West Area Health Service Cyclic peptides and uses thereof
US10138276B2 (en) 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
AU2018243571B2 (en) 2017-03-31 2024-03-07 The Board Of Trustees Of The Leland Standford Junior University Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling
CA3109702A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025122A1 (en) * 1994-03-17 1995-09-21 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
JPH04503073A (ja) * 1989-01-31 1992-06-04 アボツト・ラボラトリーズ アナフィラトキシン受容体リガンド
US5223485A (en) * 1989-01-31 1993-06-29 Abbott Laboratories Anaphylatoxin-receptor ligands
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
AU8228791A (en) * 1990-06-15 1992-01-07 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
US5387671A (en) * 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
DE69534077T2 (de) * 1994-01-14 2005-08-11 Rath, Matthias, Dr.med. Verwendung von methoden zur identifizierung von hydrophilen signal-oligopeptiden
CA2186873A1 (en) * 1994-04-01 1995-10-12 Charles J. Hackett Haptenated peptides and uses thereof
DE69617396T2 (de) * 1995-01-16 2002-09-05 Northern Sydney Area Health Service, St. Leonards T-Zellen beeinflussende Peptide
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025122A1 (en) * 1994-03-17 1995-09-21 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus

Also Published As

Publication number Publication date
CA2210812C (en) 2009-09-01
JP4522367B2 (ja) 2010-08-11
EP0804469B1 (en) 2001-11-28
JPH10512267A (ja) 1998-11-24
JP2005145985A (ja) 2005-06-09
US6057294A (en) 2000-05-02
CA2210812A1 (en) 1996-07-25
DE69617396T2 (de) 2002-09-05
ES2168456T3 (es) 2002-06-16
JP3665342B2 (ja) 2005-06-29
JP2006117697A (ja) 2006-05-11
DE69617396D1 (de) 2002-01-10
AU4427296A (en) 1996-08-07
EP0804469A4 (en) 1998-05-20
EP0804469A1 (en) 1997-11-05
WO1996022306A1 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
Manolios et al. T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease
EP0804469B1 (en) T-cell affecting peptides
US6458360B1 (en) Soluble complement regulatory molecules
JP2009029833A (ja) Ｃｄ２８／ｃｔｌａ−４阻害性ペプチド模倣物、それらの医薬組成物、およびそれらを使用する方法
WO1998023639A2 (en) ShK TOXIN COMPOSITIONS AND METHODS OF USE
RU2542375C2 (ru) Пептиды-производные ил-4 для модуляции хронического воспалительного ответа и лечения аутоиммунных заболеваний
BRPI0111191B1 (pt) moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos
Farid et al. Antiidiotypic antibodies as probes for receptor structure and function
Ostrov et al. T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues
Davidson et al. Distribution and immunoregulatory properties of antisecretory factor
DE69529515T2 (de) Die regulation der aktivität zytotoxischer t-zelllymphozyten mit peptiden der mhc-klasse i
WO1992006117A1 (en) Inhibiting unwanted immune responses
JP4452312B2 (ja) Ｔ細胞抗原受容体ペプチド
KR100333148B1 (ko) 당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체
US20100267651A1 (en) T cell antigen receptor peptides
Rosloniec et al. Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models
US4749685A (en) Immunosuppressive peptides
AU778551B2 (en) Novel peptide and screening method by using the same
WO1996031617A1 (en) Method of production of antigen-specific glycosylation inhibiting factor
WO1991018018A1 (en) Improved pseudomonas chimeric protein cytotoxic to human cells bearing il2 receptors
JP2003519162A (ja) Ｐｐ１４融合蛋白質並びに該蛋白質の製造及び使用方法